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Much evidence suggests a causal link between
HPV infection and cervical neoplasia. The HPV
subtypes are divided into three categories according
to the risk of oncogenesis (high-risk, moderate-risk and
low-risk types). The presence of high-risk HPV subty-
pes is associated with a substantial risk of cancer
(95% of cases). This link is strongest for certain HPV
types, particularly types 16, 18, 31 and 45. 
The viral genome usually exists in an episomal
(circular) configuration that can be divided into three
regions, which are known as upstream regulatory
region (URR),  early region (E), and late region (L1
and L2). Regions E6 and E7 are crucial for the pro-
cess of oncogenesis as they produce the proteins that
are necessary for the transformation of a cell. The
integration of HPV into the host cellular DNA
appears to be the final step in the transformation of
the host cell to an immortalised cancer cell capable of
invasion. Once this integration has occurred, the
expression of HPV E6 and E7 protein markedly
reduces the ability of p53 to destroy the cell  (Fig. 1).
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The presence of high-risk HPV subtypes is associated with a substantial
risk of cancer (95% of cases). This link is strongest for certain HPV types, par-
ticularly types 16, 18, 31 and 45. 
Other factors, such as smoking, nutrition, coexisting sexually transmitted
diseases and genetics, may play a role in a person’s susceptibility to HPV subty-
pes. 
Most infections must either remain permanently latent or only transiently
produce cytologic changes missed by infrequent screening. Other women will deve-
lop HPV-associated cervical disease, detectable by cytologic changes dia-
gnostic of HPV infection.
Women persistently positive for high-risk HPV types  require further
immediate evaluation by colposcopy. So HPV-testing could be used to determine
which women would be best managed by immediate colposcopy (HPV positi-
ve) and which by cytologic follow-up ( HPV negative).  
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Il cancro della cervice uterina è stato associato alla presenza di un’infezione
da HPV con  genotipo ad alto rischio nel  95% dei casi. Questa associazione
riguardava soprattutto i genotipi  16, 18, 31 e 45.
Altri fattori, quali il fumo, l’alimentazione, la presenza di altre malattie
sessualmente trasmesse e i fattori genetici, giocano un ruolo importante in  pazien-
ti  suscettibili di infezione da HPV.
Alcune volte l’infezione può rimanere permanentemente in forma latente o
solo transitoriamente produrre delle alterazioni citologiche che possono sfuggire ai
controlli di screening.
In altri casi l’infezione da HPV può evolvere verso la patologia cervicale,
producendo alterazioni citologiche diagnosticabili.
Donne risultate positive al test per la ricerca di HPV ad alto rischio sono
inviate immediatamente ad  un controllo colposcopico.
Il test per la ricerca dell’HPV può essere utile per selezionare quelle donne
che hanno bisogno di una immediata valutazione colposcopica (HPV positive) da
quelle che possono essere controllate mediante un follow-up citologico (HPV nega-
tive). 
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Fig.1 -  Integration of HPV into the host cellular DNA.
Such inhibition may render the cells sensitive to
random events that lead to the accumulation of a
genetic damage associated with cancerogenesis.
Other factors, such as smoking, nutrition, coexi-
sting sexually transmitted diseases and genetics, may
play an important role in a person’s sensitivity to
HPV subtypes. Genital HPV types are often detected
in a normal anogenital mucosa by highly sensitive
tests such as polymerase chain reaction (PCR) and
Hybrid Capture II, fulfilling the criteria of “ latent”
HPV infection, and latent HPV may be found in a
normal epithelium adjacent to expressed disease.
Latency is an extremely variable period but it is esti-
mated on average from one to eight months. It is not
clear whether clearance can occur by immune reco-
gnition at this stage or whether immune recognition
requires the increased viral numbers of a productive
infection to be stimulated. If this is the case, most
individuals have such a transient expression that
lesions are not detected.
Most infections must either remain permanently
latent or only transiently produce cytologic changes
which are usually not detected because of infrequent
screening. Other women may develop HPV-associa-
ted cervical disease, detectable by cytologic changes
diagnostic of HPV infection, including koilocytotic
atypia, or shed cells that have only some, but not all,
of the features of an HPV infection  (e.g., atypical
squamous cells of undeterminated significance or
ASCUS) (1, 2). Approximately 60% of women with
only minor atypia or SIL low grade have lesions that
will spontaneously regress in a period of ten years
and another 20-30% will not change. Those 10% who
develop high-grade SIL during the follow-up remain
persistently HPV DNA positive. 
The relative risk (RR) of the progression of the
disease from low grade SIL to carcinoma in situ
during a period of 24 months is 1.00 ( 95% CI), while
the relative risk of the progression from high-grade
SIL to carcinoma in situ is 22,65 (95% CI). After 24
months the relative risk of progression disease from
HSIL to carcinoma in situ is reduced to 4.15 (95%
CI).
An accurate and early recognition of abnormal
cytologic changes reduces the incidence of cervical
cancer. In a routine screening interval of 10 years the
incidence of cervical cancer was 20%. One or three
normal annual Pap smears are documented, the inter-
val for continued monitoring by screening Pap smears
may be lengthened at the discretion of the physician
and the patients.
Persistent or recurrent ASCUS is a particularly
problematic management issue. The addition of a
Hybrid Capture®II HPV test to cytology in the fol-
low-up of women, who resulted negative after colpo-
scopy, with “chronic” ASCUS Pap smears may be
helpful. Those women who are persistently (on two
HPV tests) HPV negative may be asked to undergo
cytologic exams every six months, provided that the
Pap remains no more abnormal than ASCUS. The
high negative predictive value of a single Hybrid
Capture®II test for CIN 2-3 and cancer is highly pro-
mising and two negative tests should reduce the theo-
retical false negative rate to a value ranging from 0.49
to 1%. In contrast, women persistently positive for
high-risk HPV types need a further immediate evalua-
tion by colposcopy. Therefore, HPV-testing could be
used to determine which women would be best
managed by immediate colposcopy  (HPV positive)
and which by cytologic follow-up ( HPV negative).
Estrogen-deficient women may have ASCUS due to
the effects of estrogen loss on the mucosa of the
lower genital tract. Therefore, before embarking on
an extensive work-up on peri or postmenopausal
women with ASCUS, the administration of a vaginal
estrogen cream before undergoing another Pap or col-
poscopy is appropriate.
The false-negative rate of screening Pap smears in
our population ranges from 20 to 30 percent. Further
procedures have been developed to address the false
negative problem of cytology reports and find
women with, or at risk of, cervical carcinoma. New
laboratory tests have been developed for primary and
secondary screening for cervical cancer and its pre-
cursors. The tests are the following: 1) Thin-layer
liquid-based cytology (ThinPrep Pap test); 2) com-
puter-assisted automated cytology (AutoPap). The
new strategies of screening include also cervico-
graphy, a visual examination which involves photo-
graphy of the cervix following acetic acid wash and
analysis of the resulting image under set conditions
by experts in colposcopy. A new visual screening pro-
cedure, speculoscopy, has been recently developed
and reported to be a further tool in detecting neopla-
stic cervical lesions, including the ones that could not
be detected through Pap smear. Speculoscopy utilises
chemiluminescence and low power magnification (4-
6x) to detect the presence or absence of aceto-white-
ned areas after applying 5% acetic acid on the cervix.
This technique seems to allow the collection of dia-
gnostic information, which is similar to the one obtai-
ned by colposcopy, but at a lower cost. 
For low-grade cervical HPV changes (CIN 1, mild
dysplasia) no treatment/observation only:
- Because both genital warts and low-grade cervi-
cal dysplasia (CIN1) often go away without treatment,
many clinicians either do not treat CIN 1 or they give
the patient the option not to treat it. It is estimated
that 50-70% of these lesions may spontaneously
resolve without treatment. Non-treatment follow-up
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usually consists of Paps every 6 months, with or
without an occasional colposcopy.
LEEP (Loop electrosurgical excision procedure)
has now become the primary treatment modality for
lesions extending into the canal and for high-grade
(CIN 3) lesions. LEEP uses a thin wire loop through
which an electrical current passes and turns the loop
into a very effective cutting tool (3). One of the pri-
mary advantages of LEEP is that the clinician can see
the lesion while it is being treated (excised) and it pro-
vides a tissue sample which can be evaluated by a
pathologist to be sure that the entire lesion is removed
and treated adequately. The relatively low cost of
LEEP and the possibility to use this procedure in the
office has eliminated the need to do hospital-based
cervical conizations in all but a minority of procedures. 
Although LEEP is largely utilised in the treatment
of large lesions, in this area laser is till regarded as the
best procedure, especially for those lesions extending
towards the cervical-vaginal margin. However, laser is
often not available and has a high cost, thus, LEEP
has virtually replaced laser even for extremely large
lesions. Laser is comparatively very costly because it
requires expensive equipment and high maintenance.
Additionally, laser requires more training and skills
than the other two procedures and implies more
serious safety issues (eye injuries and inadvertent
burns). Higher cost and the potential for easily remo-
ving an excessive amount of the cervix are its main
disadvantages. 
Cold cone is a procedure in which the clinician
removes the portion of the cervix with abnormal
cells by cutting the area through a scalpel (a surgical
knife). Since the patient usually requires a general
anaesthetic (to be put-asleep) (3), this is usually done
in an outpatient hospital operating room. Only a few
situations require a cold cone. These would include
diseases too far up the canal to be ideally removed by
LEEP and glandular diseases which may be present
in the canal.
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